Jegasothy B V, Pakes G E
University of Pittsburgh, Pennsylvania.
Clin Ther. 1991 Jan-Feb;13(1):126-41.
Oxiconazole nitrate (1%) cream became available in the United States in 1989 for the once-daily treatment of tinea pedis, tinea cruris, and tinea corporis. It has also proved valuable in the once-daily treatment of tinea (pityriasis) versicolor. In vitro oxiconazole is highly effective against many dermatophytes, including Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, and Epidermophyton floccosum. After application to the skin, oxiconazole is rapidly absorbed into the stratum corneum, maximum concentrations often being attained within 100 minutes. Fungicidal concentrations are maintained in the epidermis, upper corium, and deeper corium for at least five hours, and levels exceeding the minimum inhibitory concentrations of susceptible fungi are present in the corneum, epidermis, upper corium, and the hair follicle for over 16 hours. Applied once daily for four weeks in the treatment of tinea pedis or for two weeks in the treatment of tinea corporis, tinea cruris, and tinea versicolor, 1% oxiconazole cream has produced mycologic and clinical cures in at least 80% of patients. In plantar-type tinea pedis caused primarily by T rubrum, once-daily oxiconazole cream resulted in a mycologic cure in 76% of patients. The efficacy of once-daily and twice-daily regimens is similar. In comparative clinical trials of various types of dermatophytoses, oxiconazole was shown to be as effective as or more effective than miconazole, clotrimazole, and tolnaftate creams, and as effective as econazole and bifonazole creams. Tolerability of oxiconazole and the other antifungal creams was similar; in irritation studies oxiconazole was better tolerated than econazole. Oxiconazole cream exerts no detectable systemic effect since only a negligible amount is absorbed from the skin. Once-daily use of oxiconazole cream could be valuable in patients with a history of noncompliance with multiple-daily regimens of other topical antifungal agents.
硝酸奥昔康唑(1%)乳膏于1989年在美国上市,用于足癣、股癣和体癣的每日一次治疗。它在花斑癣(糠疹)的每日一次治疗中也被证明很有价值。在体外,奥昔康唑对许多皮肤癣菌具有高度活性,包括红色毛癣菌、须癣毛癣菌、断发毛癣菌和絮状表皮癣菌。涂抹于皮肤后,奥昔康唑迅速被角质层吸收,通常在100分钟内达到最大浓度。在表皮、上真皮层和深真皮层中,杀菌浓度至少维持5小时,在角质层、表皮、上真皮层和毛囊中,超过易感真菌最低抑菌浓度的水平可存在16小时以上。1%硝酸奥昔康唑乳膏每日一次应用四周治疗足癣,或每日一次应用两周治疗体癣、股癣和花斑癣,至少80%的患者实现了真菌学和临床治愈。在主要由红色毛癣菌引起的跖型足癣中,每日一次使用奥昔康唑乳膏使76%的患者实现了真菌学治愈。每日一次和每日两次治疗方案的疗效相似。在各类皮肤癣菌病的比较临床试验中,奥昔康唑被证明与咪康唑、克霉唑和特比萘芬乳膏效果相当或更有效,且与益康唑和联苯苄唑乳膏效果相当。奥昔康唑和其他抗真菌乳膏的耐受性相似;在刺激性研究中,奥昔康唑的耐受性优于益康唑。由于从皮肤吸收的量可忽略不计,奥昔康唑乳膏不会产生可检测到的全身作用。对于有不依从其他外用抗真菌剂每日多次用药史的患者,每日一次使用奥昔康唑乳膏可能很有价值。